Published in Vaccine on November 20, 2012
Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ (2014) 2.50
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ (2014) 2.27
Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health (2014) 1.58
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years. PLoS One (2015) 1.40
Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst (2013) 1.38
Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter. Br J Cancer (2015) 1.02
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Systematic review of model-based cervical screening evaluations. BMC Cancer (2015) 0.98
Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia. PLoS One (2015) 0.97
Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int (2013) 0.97
Triage of HPV positive women in cervical cancer screening. J Clin Virol (2015) 0.96
Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer (2014) 0.95
HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol (2015) 0.90
The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. BMC Cancer (2015) 0.90
DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer (2014) 0.87
Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol (2013) 0.87
Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. J Clin Microbiol (2015) 0.85
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol (2014) 0.85
Current cervical cancer screening knowledge, awareness, and practices among U.S. affiliated pacific island providers: opportunities and challenges. Oncologist (2014) 0.85
The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol (2013) 0.85
Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study. BMC Womens Health (2014) 0.85
Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open (2016) 0.84
Interlaboratory reproducibility and proficiency testing within the human papillomavirus cervical cancer screening program in Catalonia, Spain. J Clin Microbiol (2014) 0.84
Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer (2014) 0.84
Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework. J Clin Microbiol (2015) 0.83
HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev Med (2017) 0.83
Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst (2015) 0.83
Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. PLoS One (2016) 0.83
Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics (2016) 0.83
Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off. PLoS One (2014) 0.82
Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int (2015) 0.82
Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer (2015) 0.82
HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Curr Obstet Gynecol Rep (2013) 0.82
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS One (2015) 0.82
Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PLoS One (2013) 0.82
Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II(+) detection rates. Cancer Causes Control (2015) 0.82
Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med (2015) 0.81
Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan. Cancers (Basel) (2016) 0.81
Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, Haiti. PLoS One (2013) 0.80
Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. PLoS One (2015) 0.80
Clinical significance of human papillomavirus genotyping. J Gynecol Oncol (2016) 0.80
Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. Gynecol Oncol (2013) 0.79
Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. BMC Cancer (2013) 0.79
Answering human papillomavirus vaccine concerns; a matter of science and time. Infect Agent Cancer (2013) 0.79
Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol (2016) 0.79
Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. J Zhejiang Univ Sci B (2017) 0.79
HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect Agent Cancer (2015) 0.79
Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol (2015) 0.79
Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study. BMC Cancer (2015) 0.78
Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. Gynecol Oncol (2016) 0.78
The end of the decline in cervical cancer mortality in Spain: trends across the period 1981-2012. BMC Cancer (2015) 0.78
A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off. BMC Infect Dis (2014) 0.78
Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines. Cancer (2016) 0.78
Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. BMC Public Health (2014) 0.78
Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer (2016) 0.77
Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. Br J Cancer (2016) 0.77
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer (2016) 0.76
National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A (2016) 0.76
Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities. PLoS One (2015) 0.76
Screening of cervical cancer in Catalonia 2006-2012. Ecancermedicalscience (2015) 0.76
Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China. Oncol Lett (2017) 0.75
Systematic Comparison of Different Meta-analyses, Systematic Reviews and HTA Reports on Cervical Cancer Screening based on Cytology or HPV Test. Geburtshilfe Frauenheilkd (2016) 0.75
5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions. BMC Clin Pathol (2016) 0.75
[Epidemiology, prevention and early detection of cervical cancer]. Onkologe (Berl) (2016) 0.75
Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer (2016) 0.75
mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix. Oncol Lett (2016) 0.75
Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study. Biomed Res Int (2015) 0.75
Magnivisualizer in the early detection of cervical neoplasia. J Gynecol Oncol (2014) 0.75
Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round. Prev Med Rep (2016) 0.75
Recent advances in understanding and preventing human papillomavirus-related disease. F1000Res (2017) 0.75
Stability Study of Cervical Specimens Collected by Swab and Stored Dry Followed by Human Papillomavirus DNA Detection Using the cobas 4800 Test. J Clin Microbiol (2016) 0.75
Functional foods and their role in cancer prevention and health promotion: a comprehensive review. Am J Cancer Res (2017) 0.75
Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. Cancer Cytopathol (2015) 0.75
Screening: Cervical cancer--should we abandon cytology for screening? Nat Rev Clin Oncol (2012) 0.75
Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infect Dis (2016) 0.75
Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. PLoS One (2017) 0.75
Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br J Cancer (2017) 0.75
Digital droplet PCR (ddPCR) for the detection and quantification of HPV 16, 18, 33 and 45 - a short report. Cell Oncol (Dordr) (2017) 0.75
Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay. PLoS One (2017) 0.75
Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study. Int J Mol Sci (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet (2007) 6.02
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol (2011) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Data protection, informed consent, and research. BMJ (2004) 4.25
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA (2004) 4.01
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst (2009) 3.71
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet (2003) 2.71
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer (2004) 2.53
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst (2004) 2.32
Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer (2008) 2.30
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2008) 2.24
Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis (2005) 2.20
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10
The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07
Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Prev Med (2013) 2.07
Incidence and mortality of cervical cancer in Latin America. Salud Publica Mex (2003) 2.06
The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04
HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol (2006) 2.03
Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet (2011) 2.01
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics (2009) 1.92
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The search for low-penetrance cancer susceptibility alleles. Oncogene (2004) 1.88
Oral cancer in southern India: the influence of smoking, drinking, paan-chewing and oral hygiene. Int J Cancer (2002) 1.87
The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol (2009) 1.87
Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics (2014) 1.86
Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85
Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. Hum Mol Genet (2006) 1.84
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer (2009) 1.80
Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol (2005) 1.80
Cancer pattern and survival in a rural district in South India. Cancer Epidemiol (2009) 1.79
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer (2003) 1.77
Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer (2003) 1.74
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet (2007) 1.74
Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol (2004) 1.73
High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71
Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71
Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71
Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69